TMCnet News
Indivior Presents New Real-World Data at ASAM 2026 Annual Conference, Supporting Remission as a Treatment Outcome and Reinforcing the Clinical Benefits of Monthly Injectable Buprenorphine for Opioid Use Disorder
RICHMOND, Va., April 24, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV), a leader in the treatment of opioid use disorder (OUD), will present one new scientific poster and collaborated with VA Tech on a second poster which will be presented at the American Society of Addiction Medicine (ASAM) Annual Conference, held April 23-26, 2026, in San Diego, California. The data add to the growing body of evidence evaluating extended-release buprenorphine, a monthly injectable commercially available as SUBLOCADE®, in supporting meaningful outcomes for people living with OUD, including overdose-related outcomes and broader indicators associated with recovery. “For 25 years, Indivior has been committed to advancing science that meaningfully improves care for people living with opioid use disorder,” said Christian Heidbreder, Ph.D., Chief Scientific Officer at Indivior. “The data presented at ASAM reinforce the importance of sustained, evidence-based treatment for enabling meaningful and lasting recovery. With more than 500,000 people prescribed Indivior’s long-acting injectable therapy, we are encouraged by continued progress in expanding access to effective care.” Poster Highlights 1. Impact of OAT (MOUD) in individuals with OUD who experienced an overdose in Ontario, Canada This retrospective nested case-control study used Ontario administrative health data of more than 45,000 patients with OUD to evaluate associations between MOUD treatments, including SUBLOCADE, transmucosal buprenorphine (TM-BUP), methadone, and sustained-release oral morphine and the risk of opioid-related fatal and non-fatal overdose.
Study limitations include potential misclassification in administrative data, incomplete or inaccurate capture of opioid-related OD events and OAT use, and absence of a direct measure of OAT adherence. 2. Associations between remission from opioid use disorder and treatment-relevant outcomes Provisional findings from the Remission from OUD as a Treatment Endpoint (ROUTE Study) followed 443 participants within 0-3 months of starting treatment with SUBLOCADE for up to 12 months to understand how OUD remission (defined in this study as absence of DSM-5 symptoms except craving) relates to treatment-relevant and recovery-related outcomes. ul type="disc">
“Together, these valuable studies show that remaining on evidence-based medications can reduce the risk of overdose,” said Ann Wheeler, Vice President of Medical Affairs at Indivior. “The findings reinforce that progress in recovery extends beyond the absence of opioid use. It also includes improvements in how people feel, function, and participate in everyday life.” About SUBLOCADE® SUBLOCADE® (buprenorphine extended-release) injection, for subcutaneous use, CIII INDICATION AND HIGHLIGHTED SAFETY INFORMATION INDICATION SUBLOCADE should be used as part of a complete treatment plan that includes counseling and psychosocial support. HIGHLIGHTED SAFETY INFORMATION WARNING: RISK OF SERIOUS HARM OR DEATH WITH INTRAVENOUS ADMINISTRATION; SUBLOCADE RISK EVALUATION AND MITIGATION STRATEGY
CONTRAINDICATIONS WARNINGS AND PRECAUTIONS Respiratory Depression: Life threatening respiratory depression and death have occurred in association with buprenorphine. Warn patients of the potential danger of self-administration of benzodiazepines or other CNS depressants while under treatment with SUBLOCADE. Risk of Serious Injection Site Reactions: Likelihood may increase with inadvertent intramuscular or intradermal administration. Evaluate and treat as appropriate. The most common injection site reactions are pain, erythema, and pruritus with some involving abscess, ulceration, and necrosis. Neonatal Opioid Withdrawal Syndrome: Neonatal opioid withdrawal syndrome (NOWS) is an expected and treatable outcome of prolonged use of opioids during pregnancy. Adrenal Insufficiency: If diagnosed, treat with physiologic replacement of corticosteroids, and wean patient off of the opioid. Risk of Opioid Withdrawal with Abrupt Discontinuation: If treatment with SUBLOCADE is discontinued, monitor patients for several months for withdrawal and treat appropriately. Risk of Hepatitis, Hepatic Events: Monitor liver function tests prior to and during treatment. Risk of Withdrawal in Patients Dependent on Full Agonist Opioids: Verify that patients have tolerated transmucosal buprenorphine before injecting SUBLOCADE. Treatment of Emergent Acute Pain: Treat pain with a non-opioid analgesic whenever possible. If opioid therapy is required, monitor patients closely because higher doses may be required for analgesic effect. ADVERSE REACTIONS For more information about SUBLOCADE, the full Prescribing information including BOXED WARNING, and Medication Guide, visit www.sublocade.com.? About Opioid Use Disorder (OUD) About Indivior Media Contact: Investors Contact: 
|
